If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Jyoti Malhotra is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences
Survivors Medicine & Life Sciences
Hydroxychloroquine Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2012 2019

  • 457 Citations
  • 10 h-Index
  • 28 Article
  • 6 Review article
  • 4 Editorial
  • 1 Comment/debate

A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors

Mehnert, J. M., Kaveney, A. D., Malhotra, J., Spencer, K., Portal, D., Goodin, S., Tan, A. R., Aisner, J., Moss, R. A., Lin, H., Bertino, J. R., Gibbon, D., Doyle, L. A., White, E. P. & Stein, M. N., Jan 1 2019, (Accepted/In press) In : Cancer chemotherapy and pharmacology.

Research output: Contribution to journalArticle


Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy

Yegya-Raman, N., Reyhan, M., Kim, S., Deek, M. P., Yue, N., Zou, W., Malhotra, J., Aisner, J. & Jabbour, S., Jan 2019, In : Practical Radiation Oncology. 9, 1, p. e74-e82

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Tumor Burden
Radiation Pneumonitis

Non-Genetic Intra-Tumor Heterogeneity Is a Major Predictor of Phenotypic Heterogeneity and Ongoing Evolutionary Dynamics in Lung Tumors

Sharma, A., Merritt, E., Hu, X., Cruz, A., Jiang, C., Sarkodie, H., Zhou, Z., Malhotra, J., Riedlinger, G. M. & De, S., Nov 19 2019, In : Cell Reports. 29, 8, p. 2164-2174.e5

Research output: Contribution to journalArticle

Open Access
Genetic Heterogeneity
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Drug Therapy

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Stein, M. N., Malhotra, J., Tarapore, R. S., Malhotra, U., Silk, A. W., Chan, N., Rodriguez, L., Aisner, J., Aiken, R. D., Mayer, T., Haffty, B. G., Newman, J. H., Aspromonte, S. M., Bommareddy, P. K., Estupinian, R., Chesson, C. B., Sadimin, E. T., Li, S., Medina, D. J., Saunders, T. & 14 others, Frankel, M., Kareddula, A., Damare, S., Wesolowsky, E., Gabel, C., El-Deiry, W. S., Prabhu, V. V., Allen, J. E., Stogniew, M., Oster, W., Bertino, J. R., Libutti, S. K., Mehnert, J. M. & Zloza, A., May 22 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 136.

Research output: Contribution to journalArticle

Open Access
Oral Administration
TIC10 compound